Variations in Circulating Levels of Angiopoietin-2 Over Time Are Predictive of Ramucirumab-Paclitaxel Therapy Outcome in Advanced Gastric Cancer: Results of Prospective Study
Source : https://www.frontiersin.org/articles/10.3389/fonc.2022.862116/full
The combination of paclitaxel and ramucirumab is the second-line therapy of choice in the treatment of advanced gastric cancer. To date, no biomarkers are available in gastric cancer to predict...
Conclusion: Overall results showed that a greater change in VEGFC and Angiopoietin-2 levels measured at the beginning of the third cycle of therapy corresponded to a lower risk of progression and thus to longer progression-free survival.
Current treatments and outlook in adenocarcinoma of the esophagogastric junction: a narrative review
Source : https://atm.amegroups.com/article/view/91993/html
Adenocarcinoma of the esophagogastric junction (AEG) is a tumor of the esophagogastric junction (EGJ). Its peculiar site and biological behavior lead researchers to suggest that AEG is an independent tumor...
Conclusions: Treatments for AEG often have different plans (such as surgical treatment, neoadjuvant therapy, targeted therapy and immunotherapy) according to the pathological type of patients, the status of metastasis, and the conditions of patients. Surgical treatment is the most commonly used treatment in clinical practice. Minimally invasive...
Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603 - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35579511/
doi: 10.1093/oncolo/oyac086. Online ahead of print. 1 Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan. 2 Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan. 3 Department of...
Conclusion: Although the primary endpoint was not achieved statistically, combination therapy of ramucirumab plus irinotecan showed anticancer activity and a manageable safety profile for second-line treatment of patients with advanced gastric cancer.
The clinical position of ramucirumab-containing regimens for advanced gastric cancer: a review of clinical trial data - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35703103/
Despite the availability of multiple treatment options, the prognosis for advanced gastric cancer (AGC) remains poor and more effective treatment options are needed. Ramucirumab is an established and recommended second-line...
Relevance: Ramucirumab is a recombinant human IgG1 monoclonal antibody that targets tumor angiogenesis in the progression of gastric cancer. It does so by binding to the extracellular binding domain of the VEGFR-2 and in turn preventing it from binding to VEGFR ligands (e.g., VEGF-A, VEGF-C, VEGF-D) and blocking its activation. In 2014, two...